RESEARCH ARTICLE

Serum miR-34a-5p and miR-199a-3p as new biomarkers of neonatal sepsis

Omayma O. Abdelaleem1,*, Shereen Rashad Mohammed1, Hassan S. El Sayed1, Sherin Khamis Hussein2, Doaa Y. Ali3, Mostafa Y. Abdelwahed4, Sylvana N. Gaber5, Nada F. Hemeda6, Rehab G. Abd El-Hmid2

1 Faculty of Medicine, Departments of Medical Biochemistry and Molecular Biology, Fayoum University, Fayoum, Egypt, 2 Faculty of Medicine, Departments of Pediatrics, Fayoum University, Fayoum, Egypt, 3 Faculty of Medicine, Departments of Clinical Pathology, Fayoum University, Fayoum, Egypt, 4 Faculty of Medicine, Departments of Physiology, Fayoum University, Fayoum, Egypt, 5 Faculty of Medicine, Departments of Microbiology and Immunology, Fayoum University, Fayoum, Egypt, 6 Faculty of Agriculture, Department of Genetics, Fayoum University, Fayoum, Egypt

* dr.omayma@yahoo.com

Abstract

Background

Neonatal sepsis is a serious condition. Recent clinical studies have indicated that micro-RNAs (miRNAs) are key players in the pathogenesis of sepsis, which could be used as biomarkers for this condition.

Patients and methods

A total of 90 neonates with sepsis and 90 healthy neonates were enrolled in this study. qRT-PCR was performed to measure the expression levels of serum miR-34a-5p and miR-199a-3p.

Results

miR-34a-5p and miR-199a-3p serum levels were significantly reduced in neonates with sepsis compared with those in healthy neonates (P = 0.006 and P = 0.001, respectively). Significant correlations of miR-34a-5p and miR-199a-3p with each of TLC, RDW, RBS, and C-reactive protein (CRP) as well as SNAP-II were observed, indicating their associations with the severity of neonatal sepsis.

Conclusion

miR-34a-5p and miR-199a-3p may be useful as novel biomarkers in neonatal sepsis and may provide a new direction for its treatment.
Introduction

Neonatal sepsis is a dangerous condition associated with elevated morbidity and mortality that is caused by infection of the blood in infants within 28 days of age. In sepsis, a systemic inflammatory response occurs due to the presence of infective pathogens, resulting in superimposed secondary infections and multiple organ failure [1].

Numerous biomarkers for the diagnosis and detection of sepsis at an early stage have been identified, such as C-reactive protein (CRP), procalcitonin (PCT), and interleukins (ILs), but they have poor specificity [2]. Blood culture is widely used in the diagnosis of sepsis, but the results of culture may be delayed and false negative results are often obtained [3–5]. Therefore, there is an urgent need to identify novel biomarkers for discriminating sepsis at an early stage in addition to the possibility of their use as therapeutic targets.

MicroRNAs (miRNAs) are short noncoding RNAs associated with the regulation of gene expression. miRNAs can target numerous protein-coding genes, playing roles in inflammation, immunity, apoptosis, and cell differentiation [6]. In addition, researches have shown that the expression of miRNA is modulated at an early stage of sepsis and this is positively correlated with severity and disease progression and are considered powerful endogenous factors regulating the inflammatory signaling cascade during sepsis. Also, blockage of their proinflammatory effects can effectively improve sepsis-related organ injury, offering new insights to detect possible biomarkers and therapeutic options for sepsis [7].

Recent studies reported that serum miRNAs can act as early biomarkers in many diseases, including sepsis [8,9]. Furthermore, miRNAs are considered perfect biomarkers for sepsis due to their selectivity, specificity, and stability [10].

miR-34a-5p and miR-199a-3p are miRNAs with vital roles in the development of inflammatory and autoimmune diseases [11–14], and they were proved to be involved in the regulation of TLR signaling and NF-κB-mediated inflammatory response which have main role in the process of sepsis [15]. However, the role of miR-34a-5p and miR-199a-3p in neonatal sepsis has yet to be studied.

The purpose of the current study is to evaluate the expression levels of miR-34a-5p and miR-199a-3p in neonates with sepsis and to evaluate their relationships with laboratory and clinical data in such patients.

Patients and methods

The current study was performed on 90 neonates (33 males and 57 females), weighing 2.6 ±0.4 kg, with clinical manifestations of sepsis. The subjects were separated into two groups as follows: (1) a sepsis group with positive blood culture of septicemia, which included 76 neonates; and (2) a sepsis group with negative blood culture, which included 14 neonates. Furthermore, 90 healthy control neonates (29 males and 61 females), weighing 2.7± 0.7 kg, were enrolled in this study.

The included newborns with sepsis were hospitalized in the neonatal intensive care unit, while healthy neonates were recruited from outpatients of the pediatrics Department, Fayoum University Hospital, during the period from December 2019 to September 2020. The cases of neonatal sepsis were diagnosed according to the criteria defined at the 2003 Kunming Neonatal Sepsis Definitions Conference [16].

Neonates with chromosomal anomalies, those with perinatal asphyxia, and those with intrauterine growth retardation were excluded from this study. Moreover, neonates whose mothers were diabetic, hypertensive or had any inflammatory or autoimmune diseases were excluded from the study. Written informed consent for each neonate was given by the parents or legal guardians. The present work was approved by the Ethics Committee of Fayoum
University, in line with the Declaration of Helsinki. The Score for Neonatal Acute Physiology (SNAP II) was used in this study as a predictor of mortality and severity using six vital signs and laboratory test results [17].

Sample preparation
Blood samples (3 ml of venous blood) at the moment of drawing the blood culture were collected in tubes containing separating gel and left to clot for 15 min at room temperature, followed by centrifugation at 3000 rpm for 10 min. The separated sera were stored at −80 ºC until RNA extraction.

Extraction of miRNAs
Total RNA extraction, including of miRNAs, from serum samples was carried out using the miRNeasy Serum/Plasma kit (Qiagen, Valencia, CA, USA), in accordance with the manufacturer’s instructions. The extracted RNAs were subjected to RNA quantitation and purity measurement using a NanoDrop® (ND)-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, USA).

Reverse transcription (RT) for synthesis of cDNA
Reverse transcription was performed on total RNA in reactions at RT with a final volume of 10 μl using the miRCURY LNA RT Kit (catalog no. 339340) (Qiagen, MD, USA).

Quantitative real-time PCR (qPCR) for detection of miR-34a-5p and miR-199a-3p
Real-time PCR was carried out in the real-time cycle (PikoReal 24™ Real-Time PCR System; Thermo Scientific, Finland) using miRCURYLNA SYBR® Green Master Mix (Qiagen, MD, USA) and miRCURY LNA miRNA PCR Assays (Qiagen, MD, USA). Each reaction contained 5 μl of mercury LNASYBRGreen Master Mix, 1 μl of each primer, 3 μl of cDNA(diluted 1:30), and 1 μl of RNase-free water, reaching a final volume of 10 μl.

PCR cycling conditions were as follows: initial heat activation at 95 ºC for 2 min, followed by 40 cycles of denaturation at 95 ºC for 10 s and combined annealing/extension at 56 ºC for 60 s. Melting curve analysis was performed at 60 ºC–95 ºC to assess the specificity of the amplified products.

Gene expression relative to the internal control (2^ΔΔCt) was calculated. Fold change (FC) was considered using 2^−ΔΔCt for relative. If the FC is above 1, this means that the miRNA is overexpressed, while if it is below 1, this means that the miRNA is under expressed. The control value was set to 1 because ΔΔCt for controls equals zero and 2^0 equals one [20].

Organism isolation & identification
Each patient underwent blood culture testing using the BACTEC blood culture system 9050 (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD, USA). From each presumptive positive vial, Gram staining and subculture on blood agar and MacConkey agar plates.
were performed. The isolates were identified after incubation at 37˚C by Gram staining and analysis of colony characteristics. If budding yeast cells were seen in the Gram stain, subculture was performed in Sabouraud Dextrose Agar (Oxoid Ltd., UK) at room temperature. Germ tube was performed to differentiate *Candida albicans* from other *Candida* species. Antimicrobial sensitivity testing was performed for each bacterial isolate by the Kirby–Bauer disc diffusion technique. The results were clarified in accordance with Clinical Laboratory Standards Institute (CLSI) guidelines [21]. *Staphylococcus aureus* ATCC 25923 and *Escherichia coli* ATCC 25922 were used as controls to confirm the quality and accuracy of the testing procedures.

**Statistical methods**

The current data were prepared and statistically analyzed using Statistical Package for Social Sciences version 18. The median, interquartile range (IQR), mean, and standard deviation (SD) were used for quantitative data. Chi-squared test was carried out for qualitative data, which were presented as number and percentages. Spearman’s correlation was performed to assess the correlations of miR-34a-5p and miR-199a-3p with clinical and laboratory data. A receiver operating characteristic (ROC) curve was created to identify the cut-off point, sensitivity, and specificity of miR-34a-5p and miR-199a-3p as biomarkers for neonatal sepsis. Differences were considered to be significant at \( P \leq 0.05 \). Adjusted P-values for multiple comparisons for each marker were calculated by using the Bonferroni correction method to account for the problem of multiple testing. P-value of 0.05 was divided by the number of comparisons i.e. number of clinical variables (0.05/9).

Sample size was calculated using (G power version 3). Minimal sample size of patients was 86 in each group needed to get power level 0.90, alpha level 0.05 and medium effect size of 0.5 in the studied biomarkers between the two groups.

**Results**

**Characteristics of neonatal sepsis cases and healthy neonates**

In this study, 90 neonates with sepsis as well as 90 healthy neonates were enrolled. The detailed demographic and clinical data are presented in Table 1. No statistically significant differences were observed between the case and control groups regarding age, sex, birth weight, or weight. However, significant differences were noted between the neonatal sepsis and control neonate groups concerning gestational age, maturity, Apgar score at 1 min, respiratory rate, heart rate, head circumference, and height.

Regarding the laboratory data as presented in Table 2, there were significant differences between neonatal cases and controls regarding TLC, platelets count, RDW, absolute lymphocyte count, I/T neutrophils, random blood sugar (RBS), CRP, pH, and HCO₃⁻. SNAPiI was evaluated in neonates with sepsis to have a median (IQR) value of 15 (5–26). Furthermore, the results of blood culture in the sepsis group indicated that 76 (84.4%) of the cases were blood culture-positive, while 14 (15.6%) were negative. The distribution of identified microorganisms in positive blood cultures showed that the Gram-negative bacteria represented 55% of the total, including *Klebsiella* species (36.8%), *Enterobacter* species (11.8%), and *Acinetobacter* species (6.5%). Overall, 32% of the positive blood culture results were Gram-positive organisms, mainly *Staphylococcus aureus* (25%), followed by *Enterococcus* species (6.5%). Meanwhile, *Candida* species represented 13%. Overall, the results on antibiotic resistance among the positive blood cultures were as follows: 24 (26.7%) for AmpC beta lactamase, 14 (15.6%) for methicillin-resistant *Staphylococcus aureus* (MRSA), 13 (14.4%) involving multidrug-resistant organisms (MDRO), and 5 (5.6%) for extended-spectrum beta-lactamases (ESBL) (Table 2).
miR-34a-5p and miR-199a-3p serum levels in each group

miR-34a-5p and miR-199a-3p FC serum levels were significantly low in neonates with sepsis compared with those in healthy neonates [median (IQR)FC of miR-34a-5p was 0.42 (0.08–3.86) with a P value of 0.006, while median (IQR)FC of miR-199a-3p was 0.62(0.38–2.41) with a P value of 0.001] Fig 1 and S1 Table.

Table 1. Demographic and clinical data of neonates with sepsis and control.

|                      | Cases (N = 90) | Control (N = 90) | P-value |
|----------------------|---------------|------------------|---------|
| **Age/days**         | 11 (3–21)     | 7.1 (4–12)       | 0.711   |
| **Sex:**             |               |                  |         |
| Male, n (%)          | 33 (36.7)     | 29 (34.4)        | 0.530   |
| Female, %            | 57 (63.3)     | 61 (65.6)        |         |
| **Gestational age/weeks** | 36.1±1.9 | 37.5±0.6        | <0.0001*   |
| **Birth weight/kg**  | 2.5±0.4       | 2.6±0.7          | 0.113   |
| **Apgar score at 1 min** | 8.7±1.4 | 9.4±0.6          | <0.0001*   |
| **Respiratory rate** | 66.2±15.2     | 43.5±3.9         | <0.0001*   |
| **Heart rate**       | 135.8±17.2    | 121.3±10.9       | <0.0001*   |
| **Head circumference** | 33.5±1.7   | 34±0.9           | 0.009"    |
| **Weight/kg**        | 2.6±0.4       | 2.7±0.7          | 0.243   |
| **Height**           | 47.7±3.6      | 49.7±1.3         | <0.0001*   |
| **Maturity, n (%)**  |               |                  |         |
| Preterm              | 39 (43.3)     | 10 (11.1)        | <0.0001*   |
| Full term            | 51 (56.7)     | 80 (88.9)        |         |
| **Sepsis onset**     |               |                  |         |
| Early onset; n (%)   | 53 (58.8)     |                  |         |
| Late onset; n (%)    | 37 (41.1)     |                  |         |
| **PROM**             |               |                  |         |
| Yes, n (%)           | 29 (32.2)     |                  |         |
| No, n (%)            | 61 (67.8)     |                  |         |
| **Convulsion**       |               |                  |         |
| Yes                  | 18 (20.0)     |                  |         |
| No                   | 72 (80.0)     |                  |         |
| **Apnea**            |               |                  |         |
| Yes                  | 8 (8.9)       |                  |         |
| No                   | 82 (91.1)     |                  |         |
| **Respiratory distress (RD)** |     |                  |         |
| No                   | 19 (21.1)     |                  |         |
| RD1                  | 35 (38.9)     |                  |         |
| RD2                  | 28 (31.1)     |                  |         |
| RD3                  | 3 (4.4)       |                  |         |
| RD4                  | 4 (4.4)       |                  |         |

Data are expressed as median (IQR), mean ± SD, or n (%).

PROM: Premature rupture of membrane, RD 1: (mild distress):- tachypnea, working alanasi.
RD2: (moderate distress):- subcostal and intercostal due to moderate hypoxemia, RD3: (severe distress):- Grunting which is due to severe hypoxemia, RD4: Cyanosis and disturbed consciousness. * Significant at P < 0.05.

https://doi.org/10.1371/journal.pone.0262339.t001
To estimate the influence of the clinical characteristics and results of blood culture of neonatal sepsis cases on the levels of miR-34a-5p and miR-199a-3p, we analyzed the expression levels of these miRNAs according to the clinical characteristics and blood culture results in patients with neonatal sepsis after applying multiple testing correction (Table 3). The results showed that miR-34a-5p and miR-199a-3p were significantly downregulated in neonates with positive blood culture, mainly *Enterococcus* ($P < 0.0001$, each). In addition, miR-34a-5p was demonstrated to be significantly downregulated with bacteria showing gram negative stain ($P < 0.0001$). While, miR-199a-3p was verified to be significantly downregulated with bacteria showing gram positive stain ($P < 0.0001$).

Table 2. Laboratory data of neonates with sepsis and control group.

|                    | Cases (N = 90) | Control (N = 90) | P-value |
|--------------------|---------------|-----------------|---------|
| TLC (×10⁹ per L)   | 17.7±7.82     | 10.47±2.98      | <0.0001 |
| Platelets (×10⁹ per L) | 209.08±185.52  | 335.46±58.11   | <0.0001 |
| RDW                | 16±1.3        | 14.1±0.6        | <0.0001 |
| Lymphocyte count (10³/μL) | 6.8±4.7       | 3.7±1.01        | <0.0001 |
| I/T neutrophils    | 0.26±(0.11)   | 0.12±(0.05)     | <0.0001 |
| RBS (mg/dl)        | 111±17.4      | 98.8±11.8       | <0.0001 |
| CRP (mg/dl)        | 3.75±1.2      | 1.5±0.3         | <0.0001 |
| pH                 | 7.32±0.57     | 7.38±0.04       | <0.0001 |
| CO₂                | 41.2±11.11    | 41.9±4.5        | 0.550   |
| HCO₃               | 18.4±1.4      | 19.9±2          | <0.0001 |
| Mean ABP (mmHg)    | 53.7±13.1     |                 |         |
| Urine output (ml/kg/h) | 1.2±0.7       |                 |         |
| PO₂ (mmHg)/Fi O₂   | 2.2±0.7       |                 |         |
| SNAP II            | 15 (5–26)     |                 |         |
| Culture, n (%)     |               |                 |         |
| Positive           | 76 (84.4)     |                 |         |
| Negative           | 14 (15.6)     |                 |         |
| Organisms, n (%)   |               |                 |         |
| *Acinetobacter baumannii* | 5 (5.6)   |                 |         |
| *Candida* species  | 10 (11.1)     |                 |         |
| *Enterobacter* species | 9 (10)        |                 |         |
| *Enterococcus*     | 5 (5.6)       |                 |         |
| *Klebsiella* species | 28 (31.1)    |                 |         |
| Negative           | 14 (15.6)     |                 |         |
| *Staph. aureus*    | 19 (21.1)     |                 |         |
| Antibiotic resistance n (%) |       |                 |         |
| AmpC beta lactamase | 24 (26.7)     |                 |         |
| MDRO               | 13 (14.4)     |                 |         |
| MRSA               | 14 (15.6)     |                 |         |
| ESBL               | 5 (5.6)       |                 |         |

Data are expressed as median (IQR), mean ± SD, or n (%).

TLC: Total leucocyte count, RDW: Red cell distribution width, I/T: Immature/total, RBS: Random blood sugar, CRP: C-reactive protein, ABP: Arterial blood pressure, SNAP: Score of neonatal acute physiology, MDRO: Multidrug-resistant organisms, MRSA: Methicillin-resistant *Staphylococcus aureus*, ESBL: Extended-spectrum beta-lactamases.

*Significant at $P < 0.05$.

https://doi.org/10.1371/journal.pone.0262339.t002
Correlations of serum levels of miR-34a-5p and miR-199a-3p with clinical and laboratory parameters in sepsis group

Spearman’s analysis was used to evaluate the correlations of the serum levels of miR-34a-5p and miR-199a-3p with each of the clinical and laboratory variables (Table 4). Positive correlations were demonstrated between the serum level of miR-34a-5p and each of birth weight, weight, height, and platelet count, while it had negative correlations with TLC, RDW, RBS, CRP, as well as SNAPII. Regarding miR-199a-3p, it was found to be significantly positively correlated with birth weight, Apgar score at 1 min, weight, and platelet count, while it was negatively correlated with each of respiratory rate, heart rate, TLC, RDW, RBS, CRP, as well as SNAPII in neonates with sepsis.

Receiver operating characteristic curve (ROC) analysis

An ROC curve was created to determine the potential of the serum levels of miR-34a-5p and miR-199a-3p as predictive biomarkers for neonatal sepsis (Fig 2). For miR-34a-5p, the area
|                               | miR-34a-5p | P-value       | miR-199a-3p | P-value       |
|-------------------------------|------------|---------------|------------|---------------|
| **Sex**                       |            |               |            |               |
| Male (n = 33)                 | 0.35 (0.19–3.86) | 0.076         | 0.7 (0.51–2.41) | 0.040         |
| Female (n = 57)               | 0.48 (0.06–7.21) | 0.57 (0.21–4.89) |            |               |
| **Gestational age**           |            |               |            |               |
| Preterm                       | 0.33 (0.04–3.50) | 0.024         | 0.62 (0.38–1.30) | 0.050         |
| Full term                     | 0.51 (0.19–7.21) | 0.63 (0.51–8.51) |            |               |
| **PROM**                      |            |               |            |               |
| Yes (n = 29)                  | 2.38 (0.06–3.86) | 0.962         | 2.41 (0.38–4.89) | 0.839         |
| No (n = 61)                   | 0.33 (0.15–1.01) | 0.62 (0.41–1.04) |            |               |
| **Convulsion**                |            |               |            |               |
| Yes (n = 18)                  | 0.2 (0.04–88.03) | 0.106         | 0.27 (0.02–1.3) | 0.001         |
| No (n = 72)                   | 0.48 (0.17–3.86) | 0.63 (0.41–4.89) |            |               |
| **Respiratory distress (RD)** |            |               |            |               |
| None (n = 19)                 | 0.51 (0.48–8.88) | 0.386         | 1.04 (0.21–10.48) | 0.642         |
| RD1 (n = 35)                  | 1.01 (0.04–7.21) | 0.63 (0.57–8.51) |            |               |
| RD2 (n = 28)                  | 0.27 (0.15–3.86) | 0.51 (0.38–1.3) |            |               |
| RD3 (n = 4)                   | 0.08 (0.08–0.15) | 0.7 (0.63–0.7) |            |               |
| RD4 (n = 4)                   | 0.22 (0.15–0.22) | 0.62 (0.6–0.66) |            |               |
| **Apnea**                     |            |               |            |               |
| Yes (n = 8)                   | 0.12 (0.02–0.22) | 0.001         | 0.33 (0.03–0.62) | 0.027         |
| No (n = 82)                   | 0.48 (0.15–3.86) | 0.63 (0.41–2.41) |            |               |
| **Sepsis onset**              |            |               |            |               |
| Early onset                   | 0.35 (0.08–3.50) | 0.307         | 0.62 (0.41–1.30) | 0.912         |
| Late onset                    | 0.51 (0.19–3.86) | 0.63 (0.38–2.30) |            |               |
| **Culture**                   |            |               |            |               |
| Positive (n = 76)             | 0.33 (0.07–2.94) | <0.0001*      | 0.57 (0.38–0.87) | <0.0001*      |
| Negative (n = 14)             | 2.38 (1.01–88.03) | 8.51 (1.3–8.51) |            |               |
| **Organisms**                 |            |               |            |               |
| *Acinetobacter baumannii* (n = 5) | 0.51 (0.51–0.51) | <0.0001*      | 0.21 (0.21–0.21) | <0.0001*      |
| *Candida* species (n = 10)    | 5.85 (0.06–9.32) | 0.57 (0.38–0.57) |            |               |
| *Enterobacter* species (n = 9) | 7.21 (0.22–7.21) | 4.89 (0.62–4.89) |            |               |
| *Enterococcus* species (n = 5) | 0.04 (0.04–0.04) | 0.02 (0.02–0.02) |            |               |
| *Klebsiella* species (n = 28)  | 0.12 (0.04–0.48) | 0.6 (0.16–1.04) |            |               |
| *Staph. aureus* (n = 19)      | 0.33 (0.19–8.88) | 0.63 (0.41–10.48) |            |               |
| **Gram stain type**           |            |               |            |               |
| Negative                      | 0.15 (0.04–3.5) | <0.0001*      | 0.7 (0.38–2.3) | <0.0001*      |
| Positive                      | 0.27 (0.19–0.35) | 0.54 (0.41–0.63) |            |               |
| **Antibiotic resistance**     |            |               |            |               |
| AmpC beta lactamase (n = 24)   | 0.48 (0.07–3.86) | 0.001         | 1.04 (0.48–2.41) | 0.203         |
| MDRO (n = 13)                 | 0.08 (0.04–0.15) | 0.57 (0.16–0.62) |            |               |
| MRSA (n = 14)                 | 0.35 (0.19–8.88) | 0.57 (0.51–10.48) |            |               |
| ESBL (n = 5)                  | 0.33 (0.33–0.33) | 0.63 (0.41–0.63) |            |               |

PROM: Premature rupture of membrane, MDRO: Multidrug-resistant organisms, MRSA: Methicillin-resistant *Staphylococcus aureus*, ESBL: Extended-spectrum beta-lactamases.

*Significant at P<0.006.

[https://doi.org/10.1371/journal.pone.0262339.t003](https://doi.org/10.1371/journal.pone.0262339.t003)
under the curve (AUC) was 0.792 [95% confidence interval (CI): 0.725–0.859] with sensitivity and specificity of 66.7 and 83.3, respectively, and $P < 0.0001$. Moreover, the AUC for miR-199a-3p was 0.701 (95% CI: 0.624–0.778) with sensitivity and specificity of 66.6 and 64.4, respectively, and $P < 0.0001$. The use of a combined model consisting of miR-34a-5p and miR-199a-3p demonstrated an increase of the AUC to 0.812 (95% CI: 0.751–0.874) with sensitivity and specificity of 72.2 and 71.1, respectively, and $P < 0.0001$. However, AUC for IT ratio was 0.864 (95 CI: 0.800–0.928, $P < 0.0001$), which was near to that of combined model with sensitivity = 81.1% and specificity = 96.7 (S1 Fig).

### Multivariate analysis

Predictors that were related to sepsis by a $p$ value of $\leq 0.05$ by univariate analysis were selected to be used in the multivariable logistic regression model. HR was excluded from the model due to co-linearity with RR. Likewise, GA was excluded as it was correlated with HG and by the same manner HCO3 was related to APGAR score at one minute. Variables as Temperature, PLT, RDW, TLC, Lymph, IT ratio and PH were removed because of either zero or large value of standard error of B coefficient. Along sides with miR-199a-3p and miR-34a-5p, DBP, RR, HG, RBS and APGAR score at one minute were included in the model. After variable selection, Stepwise backward Wald method using $p<0.10$ for removal was performed (S2 Table).

| Table 4. Correlations of serum levels of miR-34a-5p and miR-199a-3p with clinical and laboratory data in neonates with sepsis. |
| --- |
| miR-34a-5p $r$ (P-value) | miR-199a-3p $r$ (P-value) |
| Age | -0.048 (0.656) | -0.123 (0.246) |
| Gestational age | 0.175 (0.098) | 0.068 (0.522) |
| Birth weight | 0.550 (<0.0001*) | 0.332 (0.001*) |
| Apgar score at 1 min | -0.087 (0.417) | 0.230 (0.029*) |
| Respiratory rate | -0.129 (0.227) | -0.211 (0.046*) |
| Heart rate | -0.147 (0.166) | -0.271 (0.010*) |
| Head circumference | 0.205 (0.053) | 0.181 (0.087) |
| Weight | 0.342 (0.001*) | 0.446 (<0.0001*) |
| Height | 0.344 (0.001*) | 0.196 (0.064) |
| TLC | -0.402 (<0.0001*) | -0.307 (0.003*) |
| Platelets | 0.497 (<0.0001*) | 0.508 (<0.0001*) |
| RDW | -0.309 (0.003*) | -0.237 (0.025*) |
| Lymph | -0.097 (0.362) | 0.040 (0.707) |
| I/T neutrophils | 0.116 (0.277) | 0.059 (0.578) |
| RBS | -0.386 (<0.0001*) | -0.291 (0.005*) |
| CRP | -0.348 (0.001*) | -0.422 (<0.0001*) |
| pH | -0.156 (0.142) | 0.168 (0.113) |
| CO$_2$ | 0.042 (0.694) | -0.007 (0.951) |
| HCO$_3$ | -0.150 (0.157) | -0.073 (0.494) |
| Mean ABP | 0.012 (0.907) | 0.107 (0.315) |
| Urine output | 0.007 (0.951) | -0.026 (0.810) |
| PO$_2$(mmHg)/FiO$_2$ | 0.009 (0.934) | 0.103 (0.333) |
| SNAP | -0.294 (0.005*) | -0.233 (0.027*) |

TLC: Total leucocyte count, RDW: Red cell distribution width, I/T: Immature/total, RBS: Random blood sugar, CRP: C-reactive protein, ABP: Arterial blood pressure, SNAP: Score of neonatal acute physiology.

*Signifcant at $P < 0.05$.

https://doi.org/10.1371/journal.pone.0262339.t004
Discussion

Neonatal sepsis is a life-threatening condition characterized by an interplay between the host immune system and invading microbial pathogens, resulting in severe systemic inflammation, which leads to multisystem failure [1]. miRNAs are short non-coding RNAs that regulate numerous biological processes. Increasing evidence suggests that miRNAs play vital roles in immune regulation in autoimmune and infectious diseases [22,23]. Various biomarkers have been considered to aid the diagnosis and prognosis of sepsis, but with limitations in severe and early cases [2,3]. Recently, much attention has focused on utilizing serum miRNAs as biomarkers for the diagnosis and prognosis of sepsis that are released outside cells into serum and remain stable in circulation, given their ease of detection [24].

It has been reported that miR-34a is a strong tumor suppressor in a variety of cancers [25,26]. The expression of miR-34a-5p has been found to be involved in the regulation of autophagy, cell cycle differentiation, and apoptosis by targeting numerous genes [27,28].

In the present study, we revealed that the serum expression level of miR-34a-5p was significantly decreased in patients with neonatal sepsis compared with that in healthy neonates.

Our results are in accordance with a previous study that revealed the downregulation of miR-34a in sepsis-induced acute lung injury through targeting fork head box O3 (FoxO3), resulting in the activation of autophagy [29]. Another study by Liu et al. suggested that the inhibition of miR-34a could regulate autophagic activity via the targeting of ATG4B in tubular
epithelial cells in acute kidney injury [30]. Additionally, a previous study revealed that miR-34a inhibited autophagy by repressing ATG9A expression in cardiomyocyte hypertrophy [31].

It was noted that autophagy activation, which was proven to regulate innate and acquired immune processes, is a key participant in neonatal sepsis. Numerous microRNAs were documented to play key roles in sepsis through modulating autophagy, such as miR-155, miR-21-3p, miR-300, and miR-23a [32]. We hypothesized that the downregulation of miR-34a-5p in neonatal sepsis could be due to its effect on autophagy, which plays a major role in this condition.

In addition, in a recent study, miR-34a-3p was reported to be notably decreased while signal transducer and activator of transcription 1 (STAT1), cytokine-induced neutrophil chemoattractant 1 (CINC-1), and intercellular adhesion molecule 1 (ICAM-1) were increased in sepsis-induced acute lung injury in rats. The aforementioned study proved that sevoflurane reduced the expression of inflammatory markers and improved the viability of lung cells via the upregulation of miR-34a-3p and repression of STAT1 [33].

However, research has shown that miRNA-34a was upregulated in neonatal lung injury patients and mice compared with the level in control groups [34]. Similarly, Cheng et al. confirmed that miR-34a expression was increased in rats with LPS-induced sepsis and U937 [35], which was not in accordance with our results.

The present results showed that miR199a-3p was significantly downregulated in the serum of neonates with sepsis, compared with that in healthy neonates. Our results are in line with a previous study that revealed remarkable downregulation of miR-199a in mice with LPS-induced ALI [36]. In addition, Chen et al. demonstrated that miR-199a-3p expression was decreased in ALI due to the binding of C-terminal-binding protein 2–histone deacetylase 1–FOXP3 transcriptional complex (CHFTC) to its promoter, resulting in elevation of the expression level of nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing protein 1 (NLRP1), which activates the release of inflammatory markers (IL-1β and IL-18), exacerbating the inflammatory response in ALI [37].

Moreover, it was documented that a significantly reduced level of miR-199a-3p leads to the upregulation of hypoxia inducible factor 1 alpha subunit (HIFA) in HCC [38]. Similarly, Rane et al. proved that miR-199a could regulate the hypoxia-triggered pathway by targeting HIFA [39]. Notably, HIFA plays a key role in the pathogenesis of sepsis [40].

Previous research revealed that miR-199a regulates the IkB kinase-beta (IKK-beta) pathway in ovarian cancer cells [41]. A report has also shown that the IKK-beta/NF-kB pathway plays a pivotal role in sepsis and is associated with multiple organ failure [42]. Considering these previous studies, we hypothesized that miR-199a-3p might play an important role in the pathogenesis of sepsis.

The current results demonstrated that miR-34a-5p and miR-199a-3p exhibited significant correlations with each of TLC, RDW, RBS, and CRP, as well as SNAPII, indicating their association with the severity of neonatal sepsis. In the line with our results, Chen et al. proved that miR-199a negatively regulated IKK-beta promoting NF-kB signaling activation [41] which in turn participated in endogenous C-reactive protein induction [43]. Moreover, Xie et al. found that miR-34a is positively correlated with numerous inflammatory markers including CRP in rheumatoid arthritis and systemic lupus erythematosus patients [44].

From the above results, we concluded that miR-34a-5p and miR-199a-3p could serve as valuable predictors of neonatal sepsis, with high specificity and sensitivity, and might function as targets for treating this condition. Furthermore, miR-34a-5p and miR-199a-3p associated significantly with the severity of neonatal sepsis.
In-depth research on a larger population is needed in future work. Further prospective studies should be carried out to investigate the mechanisms of action and the downstream genes of miR-34a-5p and miR-199a-3p during sepsis.

Supporting information
S1 Fig. ROC curve analysis of serum miR-34a-5p, miR-199a-3p and IT ratio for differentiating neonates with sepsis from healthy ones.
(TIF)
S1 Table. miR-34a-5p and miR-199a-3p fold change in neonates with sepsis.
(XLSX)
S2 Table. Multivariable logistic regression model.
(DOCX)

Author Contributions
Data curation: Mostafa Y. Abdelwahed.
Investigation: Sherin Khamis Hussein, Rehab G. Abd El-Hmid.
Methodology: Omayma O. Abdelaleem, Shereen Rashad Mohammed, Hassan S. El Sayed, Doaa Y. Ali, Sylvana N. Gaber.
Writing – review & editing: Nada F. Hemeda.

References
1. Satar M, Ozu¨ F. Neonatal sepsis: a continuing disease burden. Turk J Pediatr. 2012 Sep-Oct; 54(5):449–57. PMID: 23427506.
2. Fatmi A, Rebiahi SA, Chabni N, Zerrouki H, Azaoui H, Benmansour S, Ibáñez-Cabellos JS, Smahi MC, Arbi M, García-Giménez JL, Pallardó FV. miRNA-23b as a biomarker of culture-positive neonatal sepsis. Mol Med. 2020 Oct 8; 26(1):94. https://doi.org/10.1186/s10020-020-00217-8 PMID: 33032520
3. Wang D, Han L. Downregulation of miR-1184 serves as a diagnostic biomarker in neonatal sepsis and regulates LPS-induced inflammatory response by inhibiting IL-16 in monocytes. Exp Ther Med. 2021; 21(4):350 https://doi.org/10.3892/etm.2021.9781 PMID: 33732323
4. Delanghe JR, Speeckaert MM. Translational research and biomarkers in neonatal sepsis. ClinChimActa. 2015 Dec 7; 451(Pt A):46–64. https://doi.org/10.1016/j.cca.2015.01.031 Epub 2015 Feb 4. PMID: 25661089
5. de Prost N, Razazi K, Brun-Buisson C. Unrevealing culture-negative severe sepsis. Crit Care. 2013 Sep 26; 17(5):1001. https://doi.org/10.1186/cc13022 PMID: 24074289; PMCID: PMC4056359.
6. Gantier MP. New perspectives in microRNA regulation of innate immunity. J Interferon Cytokine Res. 2010 May; 30(5):283–9. https://doi.org/10.1089/jir.2010.0037 PMID: 20477549.
7. Chen M, Wang F, Xia H, Yao S. MicroRNA-155: Regulation of Immune Cells in Sepsis. Mediators Inflamm. 2021 Jan 8; 2021:8674854. https://doi.org/10.1155/2021/8674854 PMID: 33505221
8. Wang L, Wang HC, Chen C, Zeng J, Wang Q, Zheng L, Yu HD. Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients. ExpTher Med. 2013 Apr; 5(4):1101–4. https://doi.org/10.3892/etm.2013.937 Epub 2013 Jan 30. PMID: 23596477; PMCID: PMC3627686.
9. Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, Ferracin M, Nicoloso MS, Barbarotto E, Popa M, Stancluicea O, Fernandez MH, Tulbure D, Bueso-Ramos CE, Negrini M, Calin GA. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLOS ONE. 2009 Oct 12; 4(10):e7405. https://doi.org/10.1371/journal.pone.0007405 PMID: 19823581; PMCID: PMC2756627.
10. Szilágyi B, Fejes P, Pócsi M, Kappelmayer J, Nagy B Jr. Role of sepsis modulated circulating microRNAs. EJIFCC. 2019 Jun 24; 30(2):128–45. PMID: 31263389; PMCID: PMC6599195.
11. Song AF, Kang L, Wang YF, Wang M. MiR-34a-5p inhibits fibroblast-like synoviocytes proliferation via XBP1. Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11675–82. https://doi.org/10.26355/eurrev_202011_23812 PMID: 33275235.

12. Xia W, Chen H, Chen D, Ye Y, Xie C, Hou M. PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction. J Immunother Cancer. 2020 Oct; 8(2):e001293. https://doi.org/10.1136/jitc-2020-001293 PMID: 33159459; PMCID: PMC7589438.

13. Wangyang Y, Yi L, Wang T, Feng Y, Liu G, Li D, Zheng X. MiR-199a-3p inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes via suppressing retinoblastoma 1. Biosci Rep. 2018 Nov 13; 38(6):BSR20180982. https://doi.org/10.1042/BSR20180982 PMID: 30352835; PMCID: PMC6239273.

14. Xiong A, Wang J, Mao XL, Jiang Y, Fan Y. MiR-199a-3p modulates the function of dendritic cells involved in transplantation tolerance by targeting CD86. HLA. 2019 Dec; 94(6):493–503. https://doi.org/10.1111/tan.13677 Epub 2019 Sep 3. PMID: 31448543.

15. He X, Jing Z, Cheng G. MicroRNAs: new regulators of Toll-like receptor signalling pathways. Biomed Res Int. 2014; 2014:945169. https://doi.org/10.1155/2014/945169 PMID: 24772440.

16. Chiesa C, Panero A, Osborn JF, Simone ttio AF, Pacifico L. Diagnosis of neonatal sepsis: a clinical and laboratory challenge. Clin Chem. 2004 Feb; 50(2):279–87. https://doi.org/10.1373/clinchem.2003.025171 PMID: 14752012.

17. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAPII and SNAPP E-II: simplified newborn illness severity and mortality risk scores. J Pediatr. 2001; 138(1):92–100. https://doi.org/10.1067/mpd.2001.109608 PMID: 11148519.

18. Solayman MH, Langae T, Patel A, El-Wakeel L, El-Hamamsy M, Badary O, Johnson JA. Identification of suitable endogenous normalizers for qRT-PCR analysis of plasma microRNA expression in essential hypertension. MolBiotechnol. 2016 Mar; 58(3):179–87. https://doi.org/10.1007/s12033-015-9912-z PMID: 26798072; PMCID: PMC4758859.

19. Lange T, Stracke S, Rettig R, Lendeckel U, Kuhn J, Schlüter R, Rippe V, Endlich K, Endlich N. Identification of miR-16 as an endogenous reference gene for the normalization of urinary exosomalmiRNA expression data from CKD patients. PLOS ONE. 2017 Aug 31; 12(8):e0183435. https://doi.org/10.1371/journal.pone.0183435 PMID: 28859135; PMCID: PMC5578666.

20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec; 25(4):402–8. https://doi.org/10.1006/meth.2001.025171 PMID: 11846609.

21. CLSI. Performance standards for antimicrobial susceptibility testing. Vol. 26th ed., CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute. 2018.

22. Desvignes L, Wolf AJ, Ernst JD. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol. 2012 Jun 15; 188(12):6205–15. https://doi.org/10.4049/jimmunol.1200255 Epub 2012 May 7. PMID: 22566567; PMCID: PMC3370955.

23. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAPII and SNAPP E-II: simplified newborn illness severity and mortality risk scores. J Pediatr. 2001; 138(1):92–100. https://doi.org/10.1067/mpd.2001.109608 PMID: 11148519.

24. Minno G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLOS ONE. 2014 Feb 27; 9(2):e90005. https://doi.org/10.1371/journal.pone.0094382 PMID: 24587182; PMCID: PMC3937395.

25. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. MiR-34: a new weapon against cancer? MolTher Nucleic Acids. 2014 Dec 5; 377(1):114–9. https://doi.org/10.1016/j.mt_na.2014.07.011 PMID: 252422652.

26. Huang J, Sun W, Huang H, Ye J, Pan W, Zhong Y, Cheng C, You X, Liu B, Xiong L, Liu S. MiR-34a modulates autophagin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity. PLOS ONE. 2014 Apr 11; 9(4):e94382. https://doi.org/10.1371/journal.pone.0094382 PMID: 24728149; PMCID: PMC3984180.

27. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. BiochemBiophys Res Commun. 2008 Dec 5; 377(1):114–9. https://doi.org/10.1016/j.bbrc.2008.09.086 Epub 2008 Oct 1. PMID: 18834855.
29. Song L, Zhou F, Cheng L, Hu M, He Y, Zhang B, Liao D, Xu Z. MicroRNA-34a suppresses autophagy in alveolar type II epithelial cells in acute lung injury by inhibiting FoxO3 expression. Inflammation. 2017 Jun; 40(3):927–36. https://doi.org/10.1007/s10753-017-0537-1 PMID: 28321785; PMCID: PMC7101993.

30. Liu XJ, Hong Q, Wang Z, Yu YY, Zou X, Xu LH. MicroRNA-34a suppresses autophagy in tubular epithelial cells in acute kidney injury. Am J Nephrol. 2015; 42(2):168–75. https://doi.org/10.1159/000439185 Epub 2015 Sep 26. PMID: 26406385.

31. Pang J, Xiong H, Lin P. et al. Activation of miR-34a impairs autophagic flux and promotes cochlear cell death via repressing ATG9A: implications for age-related hearing loss. Cell Death Dis. 2017; 8, e3079. https://doi.org/10.1038/cddis.2017.462 PMID: 28981097.

32. Yin X, Xin H, Mao S, Wu G, Guo L. The role of autophagy in sepsis: protection and injury to organs. Front Physiol. 2019 Aug 23; 10:1071. https://doi.org/10.3389/fphys.2019.01071 PMID: 31507440; PMCID: PMC6716215.

33. Yuan J, Zhang Y. Sevoflurane reduces inflammatory factor expression, increases viability and inhibits apoptosis of lung cells in acute lung injury by microRNA-34a-3p upregulation and STAT1 downregulation. ChemBiol Interact. 2019; 322:109027. https://doi.org/10.1016/j.cbi.2020.109027 Epub 2020 Mar 6. PMID: 32147387.

34. Liu H, Liu W, Tang X, Wang T, Sun X, Lv J. IL-6/STAT3/miR-34a protects against neonatal lung injury patients. Mol Med Rep. 2017 Oct; 16(4):4355–61. https://doi.org/10.3892/mmr.2017.7036 Epub 2017 Jul 20. PMID: 28731182.

35. Cheng DL, Fang HX, Liang Y, Zhao Y, Shi CS. MicroRNA-34a promotes iNOS secretion from pulmonary macrophages in septic suckling rats through activating STAT3 pathway. Biomed Pharmacother. 2018 Sep; 105:1276–82. https://doi.org/10.1016/j.biopha.2018.06.063 Epub 2018 Jun 22. PMID: 30021364.

36. Cai ZG, Zhang SM, Zhang Y, Zhou YY, Wu HB, Xu XP. MicroRNAs are dynamically regulated and play an important role in LPS-induced lung injury. Can J PhysiolPharmacol. 2012 Jan; 90(1):37–43. https://doi.org/10.1139/y11-095 Epub 2011 Dec 20. PMID: 22185353.

37. Chen Z, Dong WH, Chen Q, Li QG, Qiu ZM. Downregulation of miR-199a-3p mediated by the CtBP2-HDAC1-FOXP3 transcriptional complex contributes to acute lung injury by targeting NLRP1. Int J Biol Sci. 2019 Sep 8; 15(12):2627–40. https://doi.org/10.7150/ijbs.37133 PMID: 31754335; PMCID: PMC6854378.

38. Jia XQ, Cheng HQ, Qian X, Bia CX, Shi ZM, Zhang JP, Feng ZQ. Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma. Cell BiochemBiophys. 2012 Jan; 62(1):237–44. https://doi.org/10.1007/s12013-011-9263-8 PMID: 21847633.

39. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, Vatner DE, Vatner SF, Abdellatif M. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009 Apr 10; 104(7):879–86. https://doi.org/10.1161/CIRCRESAHA.108.193102 Epub 2009 Mar 5. PMID: 19265035; PMCID: PMC3332328.

40. Frede S, Stockmann C, Freitag P, Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κappaB. Biochem J. 2006 Jun 15; 396(3):517–27. https://doi.org/10.1042/BJ20051839 PMID: 16583170; PMCID: PMC1482811.

41. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene. 2008 Aug 7; 27(34):4712–23. https://doi.org/10.1038/onc.2008.112 Epub 2008 Apr 14. PMID: 18408758; PMCID: PMC3041589.

42. Coldewey SM, Rogazzo M, Collino M, Patel NS, Thiernemann C. Inhibition of IKK beta kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. Dis Model Mech. 2013 Jul; 6(4):1031–42. https://doi.org/10.1242/dmm.012435 Epub 2013 May 2. PMID: 23649820; PMCID: PMC3701222.

43. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. *Immunology*. 2003; 108(4):539–547. https://doi.org/10.1046/j.1365-2567.2003.01608.x PMID: 12667216.

44. Xie M, Wang J, Gong W, Xu H, Pan X, Chen Y, Ru S, Wang H, Chen X, Zhao Y, Li J, Yin Q, Xia S, Zhou X, Liu X, Shao Q. NF-κB-driven miR-34a impairs Treg/Th17 balance via targeting Foxp3. J Autoimmun. 2019 Aug; 102:96–113. https://doi.org/10.1016/j.jaut.2019.04.018 PMID: 31130368.